自身免疫性肝炎的二线药物治疗现状

胡智超; 凡小丽; 沈怡; 杨丽

doi:10.3969/j.issn.1001-5256.2018.05.042

自身免疫性肝炎的二线药物治疗现状

DOI: 10.3969/j.issn.1001-5256.2018.05.042

四川大学华西医院消化内科

基金项目:

国家自然科学基金(82770568)；

详细信息

中图分类号: R975.5
计量
- 文章访问数: 2339
- HTML全文浏览量: 53
- PDF下载量: 485
- 被引次数: 0
出版历程
- 出版日期: 2018-05-20

Current status and recent progress of second-line drugs for autoimmune hepatitis

Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China

Research funding:

摘要

摘要:
自身免疫性肝炎(AIH)是一种由免疫反应介导的、以肝细胞为靶细胞的肝实质炎症,对于AIH标准治疗方案应答不佳或者不耐受的患者,可以使用二线治疗药物替代治疗。综述了AIH的二线药物治疗研究进展。
- 肝炎,自身免疫性 /
- 药物疗法 /
- 综述
Abstract:
Autoimmune hepatitis ( AIH) is an immune-mediated liver parenchymal inflammation with hepatocytes as target cells. Second-line drugs can be used for patients who have suboptimal response or intolerance to the standard treatment of AIH. This article reviews the research advances in second-line drugs for AIH.
- hepatitis, autoimmune /
- drug therapy /
- review

HTML全文

参考文献(37)

[1]TERZIROLI BERETTA-PICCOLI B, MIELI-VERGANI G, VERGANI D.Autoimmune hepatitis:standard treatment and systematic review of alternative treatments[J].World J Gastroenterol, 2017, 23 (33) :6030-6048.

[2]MANNS MP, CZAJA AJ, GORHAM JD, et al.Diagnosis and management of autoimmune hepatitis[J].Hepatology, 2010, 51 (6) :2193-2213.

[3]HENEGHAN MA, YEOMAN AD, VERMA S, et al.Autoimmune hepatitis[J].Lancet, 2013, 382 (9902) :1433-1444.

[4]GRNBK L, VILSTRUP H, JEPSEN P.Autoimmune hepatitis in Denmark:incidence, prevalence, prognosis, and causes of death.A nationwide registry-based cohort study[J].J Hepatol, 2014, 60 (3) :612-617.

[5]European Association for the Study of the Liver.EASL clinical practice guidelines:autoimmune hepatitis[J].J Hepatol, 2015, 63 (4) :971-1004.

[6]MONTANO-LOZA AJ, CARPENTER HA, CZAJA AJ.Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease[J].Hepatology, 2007, 46 (4) :1138-1145.

[7]MONTANO-LOZA AJ, CARPENTER HA, CZAJA AJ.Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis[J].Am J Gastroenterol, 2008, 103 (8) :1944-1951.

[8]SELVARAJAH V, MONTANO-LOZA AJ, CZAJA AJ.Systematic review:managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs[J].Aliment Pharmacol Ther, 2012, 36 (8) :691-707.

[9]CZAJA AJ.Safety issues in the management of autoimmune hepatitis[J].Expert Opin Drug Saf, 2008, 7 (3) :319-333.

[10]CZAJA AJ.Current and prospective pharmacotherapy for autoimmune hepatitis[J].Expert Opin Pharmacother, 2014, 15 (12) :1715-1736.

[11]CZAJA AJ.Drug choices in autoimmune hepatitis:part A-steroids[J].Expert Rev Gastroenterol Hepatol, 2012, 6 (5) :603-615.

[12]WIEGAND J, SCHLER A, KANZLER S, et al.Budesonide in previously untreated autoimmune hepatitis[J].Liver Int, 2005, 25 (5) :927-934.

[13]CSEPREGI A, ROCKEN C, TREIBER G, et al.Budesonide induces complete remission in autoimmune hepatitis[J].World J Gastroenterol, 2006, 12 (9) :1362-1366.

[14]ZANDIEH I, KRYGIER D, WONG V, et al.The use of budesonide in the treatment of autoimmune hepatitis in Canada[J].Can J Gastroenterol, 2008, 22 (4) :388-392.

[15]MANNS MP, WOYNAROWSKI M, KREISEL W, et al.Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis[J].Gastroenterology, 2010, 139 (4) :1198-1206.

[16]CZAJA AJ, LINDOR KD.Failure of budesonide in a pilot study of treatment dependent autoimmune hepatitis[J].Gastroenterology, 2000, 119 (5) :1312-1316.

[17]GEIER A, GARTUNG C, DIETRICH CG, et al.Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis:influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC[J].World J Gastroenterol, 2003, 9 (12) :2681-2685.

[18]LOHSE AW, GIL H.Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment[J].J Hepatol, 2011, 54 (4) :837-839.

[19]ALLISON AC, EUGUI EM.Mycophenolate mofetil and its mechanisms of action[J].Immunopharmacology, 2000, 47 (2-3) :85-118.

[20]ZACHOU K, GATSELIS N, PAPADAMOU G, et al.Mycophenolate for the treatment of autoimmune hepatitis:prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients[J].J Hepatol, 2011, 55 (3) :636-646.

[21]EFE C, HAGSTRM H, YTTING H, et al.Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J].Clin Gastroenterol Hepatol, 2017, 15 (12) :1950-1956.

[22]CZAJA AJ.Advances in the current treatment of autoimmune hepatitis[J].Dig Dis Sci, 2012, 57 (8) :1996-2010.

[23]ADAMS B, LAZARCHICK J, MEDINA AM, et al.Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis[J].Am J Hematol, 2010, 85 (8) :627-629.

[24]ANDERKA MT, LIN AE, ABUELO DN, et al.Reviewing the evidence for mycophenolate mofetil as a new teratogen:case report and review of the literature[J].Am J Med Genet A, 2009, 149A (6) :1241-1248.

[25]TANNOUS MM, CHENG J, MUNIYAPPA K, et al.Use of tacrolimus in the treatment of autoimmune hepatitis:a single centre experience[J].Aliment Pharmacol Ther, 2011, 34 (3) :405-407.

[26]YEOMAN AD, WESTBROOK RH, ZEN Y, et al.Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis[J].Hepatology, 2011, 53 (3) :926-934.

[27]MALEKZADEH R, NASSERI-MOGHADDAM S, KAVIANI MJ, et al.Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis[J].Dig Dis Sci, 2001, 46 (6) :1321-1327.

[28]NASSERI-MOGHADDAM S, NIKFAM S, KARIMIAM S, et al.Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis:interim analysis report of a randomized controlled trial[J].Middle East J Dig Dis, 2013, 5 (4) :193-200.

[29]CZOCK D, KELLER F, RASCHE FM, et al.Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids[J].Clin Pharmacokinet, 2005, 44 (1) :61-98.

[30]KERKAR N, DUGAN C, RUMBO C, et al.Rapamycin successfully treats posttransplant autoimmune hepatitis[J].Am J Transplant, 2005, 5 (5) :1085-1089.

[31]CASANOVAS T, ARGUDO A, PENA-CALA MC.Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant:three case reports[J].Transplant Proc, 2011, 43 (6) :2233-2236.

[32]VEROUX M, TALLARITA T, CORONA D, et al.Sirolimus in solid organ transplantation:current therapies and new frontiers[J].Immunotherapy, 2011, 3 (12) :1487-1497.

[33]BURAK KW, SWAIN MG, SANTODOMINO-GARZON T, et al.Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy[J].Can J Gastroenterol, 2013, 27 (5) :273-280.

[34]COOPER N, ARNOLD DM.The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases[J].Br J Haematol, 2010, 149 (1) :3-13.

[35]CHAKRAVARTY EF, MURRAY ER, KELMAN A, et al.Pregnancy outcomes after maternal exposure to rituximab[J].Blood, 2011, 117 (5) :1499-1506.

[36]de BOER NK, van NIEUWKERK CM, APARICIO PAGES MN, et al.Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine[J].Eur J Gastroenterol Hepatol, 2005, 17 (4) :457-461.

[37]HBENER S, OO YH, THAN NN, et al.Efficacy of 6-mercaptopurine as second-line treatment for patient with autoimmune hepatitis and azathioprine intolerance[J].Clin Gastroenterol Hepatol, 2016, 14 (3) :445-453.

施引文献

资源附件(0)

访问统计